JNJ Stelara FDA Approval: Pediatric Ulcerative Colitis

Johnson & Johnson’s Stelara (ustekinumab) won FDA approval on Friday for moderately to severely active ulcerative colitis in children ages 2 and older. The decision completes a pediatric sweep: Stelara is now the first monoclonal antibody that does not target TNFα approved for both main forms of pediatric IBD, following its April 15 approval for pediatric Crohn’s disease.

J&J shares closed at $268.04 on the news. Stelara, an IL-12/23 inhibitor first approved for plaque psoriasis in 2009, grew into one of the company’s biggest drugs and later expanded to psoriatic arthritis, adult Crohn’s disease, and adult ulcerative colitis. The new pediatric label adds a niche patient population, not a growth engine.

The mechanism is the point. TNF inhibitors such as infliximab and adalimumab were previously the only biologic options for pediatric ulcerative colitis. Stelara works differently, blocking IL-12 and IL-23, two cytokines that drive separate inflammation pathways. For the roughly 25% to 40% of patients who do not respond to or lose response to anti-TNF therapy, that is a genuinely new option. Newer oral and biologic agents approved for adults have generally lagged behind in pediatric labels, so a second pediatric mechanism matters.

The approval leaned on efficacy data from adult ulcerative colitis studies, plus the 52-week UNIFI-Jr study in 112 pediatric UC patients ages 3 to 17 and pharmacokinetic and safety data from pediatric Crohn’s subjects. The most common side effects were nasopharyngitis, headache, and abdominal pain. Stelara is given as an intravenous induction dose followed by subcutaneous maintenance injections, a regimen pediatric Crohn’s patients already know.

About 100,000 American children and adolescents under 20 live with inflammatory bowel disease, and roughly a quarter of all IBD cases first appear before age 20, so pediatric labels carry real clinical weight. For investors, though, the commercial impact is modest. Pediatric ulcerative colitis is a small population, which is why the FDA granted Orphan Drug Designation. That designation carries seven years of US market exclusivity for the pediatric indication, which could shield this niche from biosimilars even as the adult label loses protection. Stelara’s broader franchise is already shrinking: global sales fell 43% year over year to $1.65 billion in the second quarter as biosimilars launched in early 2025 eroded the adult market. The wider IBD field is crowded with TL1A antibodies and oral IL-23 pills in late-stage trials, but pediatric labels for those agents remain years away, so Stelara has a clear run in children for now.

What to watch next: whether J&J’s next-generation IL-23 drug Tremfya (guselkumab) can absorb Stelara’s decline fast enough, and whether Stelara holds its pediatric IBD position in the meantime.

What It Means for the Trade

This is a franchise-defense approval, not a growth event — a $1.65 billion-and-shrinking drug adding orphan-protected niche revenue while biosimilars eat the adult label. The trade-relevant part is the seven years of US exclusivity attached to the pediatric indication: it keeps a revenue stream alive inside a franchise that would otherwise be in pure decline, and it gives J&J a defensive franchise-bridging asset while Tremfya scales. Pediatric specialists now have a non-TNF option in both pediatric Crohn’s and pediatric UC, which consolidates prescribing loyalty to J&J’s immunology portfolio in a population that carries into adulthood.

The cadence to watch is Tremfya’s absorption rate — whether its growth line crosses Stelara’s decline line fast enough to keep total IL-12/23 franchise revenue flattening rather than falling. This pediatric label slows the bleed at the margin; it does not change the slope much.

Mechanism and Market Context

The clinical logic is about sequence-of-therapy, not first-line competition. Anti-TNF agents remain the first biologic most pediatric UC patients receive; Stelara’s value is as the second mechanism when TNF blockers fail or lose response — which happens in a quarter to 40% of patients. An IV induction followed by subcutaneous maintenance is also a familiar, low-burden regimen for families already managing chronic infusion schedules, and the UNIFI-Jr data package plus adult extrapolation gave the FDA a low-risk evidentiary basis.

The orphan designation economics deserve emphasis: seven years of exclusivity applies to the pediatric indication independent of the adult patent position, so biosimilar ustekinumab entrants cannot touch the children’s market. That is a rare defensive asset in the biosimilar era, and it explains why J&J bothered completing the pediatric sweep on a declining franchise.

Risks and What Could Go Wrong

1. Tremfya transition failure. If guselkumab does not capture the adult IL-23 share fast enough, the whole immunology bridge sags no matter what the pediatric label protects.
2. Biosimilar pediatric creep. Off-label biosimilar use in children is a real behavior in cost-pressed systems, exclusivity or not, especially at 43% YoY price erosion in the adult market.
3. Next-gen pediatric entrants. TL1A antibodies and oral IL-23 pills in late-stage adult trials will eventually chase pediatric labels; when they do, the non-TNF differentiation narrows.
4. Small-population math. Even with exclusivity, the pediatric UC population is small enough that reimbursement friction can cap realized revenue below the market’s modest expectations.

Net: smart defensive label work on a melting asset. No position-building signal here; the J&J immunology trade remains the Tremfya handoff.